← All candidates
13 insider buys in the last year — $586.3K in all.
13 filings on record.
GLSIGreenwich LifeSciences, Inc.
NasdaqCM · Healthcare · $230.01M
$15.45
+0.25% · Sep 15
13 insider buys in the last year — $586.3K in all.
Nothing in the last fortnight.
Price · 1Y · daily● 13 buys
▸ hover a marker for the filing · drag to zoom · daily bars sharpen to 30-min on close ranges · 4 moves explained
AI brief · from the filings on this pagePro
The filings, the score and the setup on this page, read for you in about ten seconds — what the insiders did, and what stands against it.
Market cap
$230.01M
Float
7.6M
52% public
Short % float
Pro
The buyers
▸ each insider's past open-market buys, measured ~6 months (120 trading days) later, against the S&P over the same spans · split-adjusted · pre-scheduled 10b5-1 plan trades excluded · past outcomes, not predictions
CEO and CFO
Patel Snehal
Bought $91.8K on Dec 31 — 4,300 sh @ $21.36, held direct, 0.1% of their stake.
1 of 1 position beat the S&P
The record
newest first
DateTypeInsiderOf stakeShares @ priceValue
8 more transactions on Pro →Context
Wall St
$57.00 avg target
+268.9% vs today · 2 analysts
▸ relayed analyst opinion, which tends to run optimistic — not our forecast or advice
Earnings · EPS vs forecast
1 of 4 quarters beat
Q1 '26−$0.39 act−$0.04
Q4 '25−$0.58 act−$0.26
Q3 '25−$0.30 act+$0.06
Q2 '25−$0.30 act−$0.06
Coverage
GLSI Stock Climbs After Removing A Key Overhang – Retail Turns Focus To High-Stakes Breast Cancer TrialStocktwits · 06-01Insiders of Greenwich LifeSciences, Inc. (NASDAQ:GLSI) must be frustrated after market cap dropped US$50m since recent purchasesSimply Wall St. · 01-23Greenwich LifeSciences Gets FDA Approval for GP2 for Breast Cancer Recurrence TrialMT Newswires · 01-22Several Insiders Invested In Greenwich LifeSciences Flagging Positive NewsSimply Wall St. · 11-14
The file stays open
13 filings on record.
The next one will be too.
▸ SEC EDGAR · FINRA · Nasdaq — public sources only · research, not advice